FDA Clears First Blood Test for Alzheimer’s Diagnosis
Plasma assessment is not intended as a screening or stand-alone diagnostic test, agency says
Related Articles
What Does Persistently Active Disease Mean for Patients?
Systemic lupus erythematosus (SLE) is a highly unpredictable disease characterized by significant variability between patients, which makes both prediction and management particularly challenging. In a…
H5N1 Bird Flu Cases Have Slowed in Animals and People
However, CDC researchers recommend continued surveillance
Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints
Interventional clinical trials in acute severe ulcerative colitis (ASUC) are characterized by substantial heterogeneity due to a lack of consensus in several key areas of…
Alzheimer’s Drug Used Mainly by Relatively Affluent, Urban White Men
Large disparities in who receives lecanemab, Medicare analysis suggests
Brain Dead Georgia Woman Must Carry Fetus to Birth Because of Abortion Ban
State law bans abortion after cardiac activity can be detected, around 6 weeks into pregnancy
Resource for Prescribing Methotrexate to Patients With Atopic Dermatitis
A recently published systematic review was designed as a resource for prescribing methotrexate off-label for patients with atopic dermatitis (AD). The review, which appears in…
Mystery Brain Disease in New Brunswick May Not Have Been a Mystery After All
Study sheds light on cluster of Canadians with symptoms that appeared to resemble prion disease
Opinion | Should ‘No Margin, No Mission’ Apply to the AMA?
Ahead of a June meeting, members should contact their representatives
Julia Lai-Kwon, MBBS, on Integrating PRO Measurements in Advanced Cancer Care
Patient-reported outcome (PRO) measurements are an essential component of comprehensive, patient-centered care, including for gynecological oncology patients. Implementing PROs, however, can be challenging, including knowing…